Keros Therapeutics Focuses on Advancing KER-065 for Duchenne Muscular Dystrophy (DMD)
Keros Therapeutics announced a strategic realignment designed to reallocate resources towards the development of its key clinical program, KER-065 for Duchenne muscular dystrophy (DMD).Keros...
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
Dyne Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to DYNE-251 for the treatment of patients with...
High Anti-AAV Antibodies May No Longer Be a Barrier to Elevidys Administration
One of the most significant obstacles to the application of Elevidys gene therapy developed for Duchenne muscular dystrophy disease is the high anti-AAV antibodies....
MetrioPharm’s MP1032 Receives EMA Orphan Drug Designation in Duchenne Muscular Dystrophy
MetrioPharm announced today that the European Medicines Agency has granted Orphan Drug Designation (ODD) to its lead compound, MP1032 for the treatment of children...
FDA: ‘Elevidys Gene Therapy Will Continue to Be Used in Ambulatory DMD Patients’
Elevidys, a gene therapy for Duchenne Muscular Dystrophy (DMD) from Sarepta Therapeutics, is now available to ambulatory patients, and the U.S. Food and Drug...